M42 is an Abu Dhabi-based, global tech-enabled healthcare company operating at the forefront of medical advancement. The company is seeking to transform lives through innovative clinical solutions that can solve the world’s most critical health and diagnostic challenges. By harnessing unique medical and data-centric technologies, including genomics and AI, M42 is transforming the traditional healthcare ecosystem and delivering the highest level of precise, patient-centric, and preventative care. M42 has over 20,000 employees and more than 450 facilities in 25 countries around the world. M42 owns a wide portfolio of assets that includes Amana Healthcare, Biogenix Labs, Danat Al Emarat, Diaverum, HealthPoint Hospital, the HealthPlus network of specialty centers, Moorfields Eye Hospital Abu Dhabi, Imperial College London Diabetes Centre, Insights Research Organization & Solutions (IROS), Omics Center of Excellence and National Reference Laboratory, among others.